ID

43687

Beschrijving

Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00367250

Link

https://clinicaltrials.gov/show/NCT00367250

Trefwoorden

Versies (2)
  1. 04-05-17 04-05-17 -
  2. 20-09-21 20-09-21 -
Geüploaded op

20 september 2021

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Metastatic Breast Cancer NCT00367250

Engels

Eligibility Metastatic Breast Cancer NCT00367250

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of metastatic breast cancer
Beschrijving

Secondary malignant neoplasm of female breast

Datatype

boolean

Alias
UMLS CUI [1]
C0346993
presence of at least 1 measurable lesion according to modified recist criteria
Beschrijving

Measurable Disease Quantity

Datatype

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
evidence (fluorescence in situ hybridization fish) of
Beschrijving

Evidence Fluorescent in Situ Hybridization

Datatype

boolean

Alias
UMLS CUI [1,1]
C0332120
UMLS CUI [1,2]
C0162789
her-2 overexpression in tumor tissue:group a: her-2 +++, group b: her-2 + or ++
Beschrijving

HER-2 protein overexpression Tumor tissue | HER2 Positive Score

Datatype

boolean

Alias
UMLS CUI [1,1]
C1515560
UMLS CUI [1,2]
C0475358
UMLS CUI [2,1]
C3898879
UMLS CUI [2,2]
C0449820
egfr-expressing disease as assessed by immunohistochemistry
Beschrijving

Disease Epidermal Growth Factor Receptor expression | Immunohistochemistry Assessment

Datatype

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0034802
UMLS CUI [1,3]
C0597360
UMLS CUI [2,1]
C0021044
UMLS CUI [2,2]
C1516048
recovered from relevant toxicities from other treatment prior to study entry
Beschrijving

Toxicity Due to Therapeutic procedure | Patient recovered

Datatype

boolean

Alias
UMLS CUI [1,1]
C0600688
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C0087111
UMLS CUI [2]
C1115804
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with trastuzumab for metastatic breast cancer (adjuvant therapy is allowed)
Beschrijving

trastuzumab | Adjuvant therapy Secondary malignant neoplasm of female breast

Datatype

boolean

Alias
UMLS CUI [1]
C0728747
UMLS CUI [2,1]
C0677850
UMLS CUI [2,2]
C0346993
prior treatment with cetuximab
Beschrijving

cetuximab

Datatype

boolean

Alias
UMLS CUI [1]
C0995188
concomitant cytotoxic chemotherapy
Beschrijving

Cytotoxic Chemotherapy

Datatype

boolean

Alias
UMLS CUI [1]
C0677881
treatment with any investigational agent(s) within 4 weeks prior to study entry
Beschrijving

Investigational New Drugs

Datatype

boolean

Alias
UMLS CUI [1]
C0013230
known allergic/hypersensitivity reaction to any of the components of study treatments
Beschrijving

Hypersensitivity Component Investigational Therapy

Datatype

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1705248
UMLS CUI [1,3]
C0949266
severe dyspnea
Beschrijving

Dyspnea Severe

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013404
UMLS CUI [1,2]
C0205082
myocardial infarction within 6 months prior to study entry, uncontrolled congestive heart failure; or any current grade 3 or 4 cardio-vascular disorder despite treatment
Beschrijving

Myocardial Infarction | Congestive heart failure Uncontrolled | Cardiovascular Disease New York Heart Association Classification

Datatype

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2,1]
C0018802
UMLS CUI [2,2]
C0205318
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C0007222
UMLS CUI [3,3]
C1275491
history of significant neurologic or psychiatric disorders
Beschrijving

nervous system disorder | Mental disorders

Datatype

boolean

Alias
UMLS CUI [1]
C0027765
UMLS CUI [2]
C0004936
Terug naar het begin van de pagina

Similar models

Eligibility Metastatic Breast Cancer NCT00367250

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Secondary malignant neoplasm of female breast
Item
diagnosis of metastatic breast cancer
boolean
C0346993 (UMLS CUI [1])
Measurable Disease Quantity
Item
presence of at least 1 measurable lesion according to modified recist criteria
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Evidence Fluorescent in Situ Hybridization
Item
evidence (fluorescence in situ hybridization fish) of
boolean
C0332120 (UMLS CUI [1,1])
C0162789 (UMLS CUI [1,2])
HER-2 protein overexpression Tumor tissue | HER2 Positive Score
Item
her-2 overexpression in tumor tissue:group a: her-2 +++, group b: her-2 + or ++
boolean
C1515560 (UMLS CUI [1,1])
C0475358 (UMLS CUI [1,2])
C3898879 (UMLS CUI [2,1])
C0449820 (UMLS CUI [2,2])
Disease Epidermal Growth Factor Receptor expression | Immunohistochemistry Assessment
Item
egfr-expressing disease as assessed by immunohistochemistry
boolean
C0012634 (UMLS CUI [1,1])
C0034802 (UMLS CUI [1,2])
C0597360 (UMLS CUI [1,3])
C0021044 (UMLS CUI [2,1])
C1516048 (UMLS CUI [2,2])
Toxicity Due to Therapeutic procedure | Patient recovered
Item
recovered from relevant toxicities from other treatment prior to study entry
boolean
C0600688 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C1115804 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
trastuzumab | Adjuvant therapy Secondary malignant neoplasm of female breast
Item
prior treatment with trastuzumab for metastatic breast cancer (adjuvant therapy is allowed)
boolean
C0728747 (UMLS CUI [1])
C0677850 (UMLS CUI [2,1])
C0346993 (UMLS CUI [2,2])
cetuximab
Item
prior treatment with cetuximab
boolean
C0995188 (UMLS CUI [1])
Cytotoxic Chemotherapy
Item
concomitant cytotoxic chemotherapy
boolean
C0677881 (UMLS CUI [1])
Investigational New Drugs
Item
treatment with any investigational agent(s) within 4 weeks prior to study entry
boolean
C0013230 (UMLS CUI [1])
Hypersensitivity Component Investigational Therapy
Item
known allergic/hypersensitivity reaction to any of the components of study treatments
boolean
C0020517 (UMLS CUI [1,1])
C1705248 (UMLS CUI [1,2])
C0949266 (UMLS CUI [1,3])
Dyspnea Severe
Item
severe dyspnea
boolean
C0013404 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
Myocardial Infarction | Congestive heart failure Uncontrolled | Cardiovascular Disease New York Heart Association Classification
Item
myocardial infarction within 6 months prior to study entry, uncontrolled congestive heart failure; or any current grade 3 or 4 cardio-vascular disorder despite treatment
boolean
C0027051 (UMLS CUI [1])
C0018802 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0007222 (UMLS CUI [3,2])
C1275491 (UMLS CUI [3,3])
nervous system disorder | Mental disorders
Item
history of significant neurologic or psychiatric disorders
boolean
C0027765 (UMLS CUI [1])
C0004936 (UMLS CUI [2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial